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Abstract 18 
Background 19 
Cohorts of severely ill patients with COVID-19 have been described in several countries around the 20 
globe, but to date there have been few published reports from the United Kingdom (UK). 21 
Understanding the characteristics of the affected population admitted to intensive care units (ICUs) 22 
in the UK is crucial to inform clinical decision making, research and planning for future waves of 23 
infection. 24 
 25 
Methods 26 
We conducted a prospective observational cohort study of all patients with COVID-19 admitted to a 27 
large UK ICU from March to May 2020 with follow-up to June 2020. Data were collected from health 28 
records using a standardised template. We used multivariable logistic regression to analyse the 29 
factors associated with ICU survival. 30 
 31 
Results 32 
Of the 156 patients included, 112 (72%) were male, 89 (57%) were overweight or obese, 68 (44%) 33 
were from ethnic minorities, and 89 (57%) were aged over 60 years of age. 136 (87%) received 34 
mechanical ventilation, 77 (57% of those intubated) were placed in the prone position and 95 (70% 35 
of those intubated) received neuromuscular blockade. 154 (99%) patients required cardiovascular 36 
support and 44 (28%) required renal replacement therapy. Of the 130 patients with completed ICU 37 
episodes, 38 (29%) died and 92 (71%) were discharged alive from ICU. In multivariable models, age 38 
(OR 1.13 [95% CI 1.07-1.21]), obesity (OR 3.06 [95% CI 1.16-8.74]), lowest P/F ratio on the first day of 39 
 3 
admission (OR 0.82 [95% CI 0.67-0.98]) and PaCO2 (OR 1.52 [95% CI 1.01-2.39]) were independently 40 
associated with ICU death. 41 
 42 
Conclusions 43 
Age, obesity and severity of respiratory failure were key determinants of survival in this cohort. 44 
Multiorgan failure was prevalent. These findings are important for guiding future research and 45 
should be taken into consideration during future healthcare planning in the UK.  46 
 4 
Introduction 47 
The global pandemic of coronavirus disease 2019 (COVID-19), the illness caused by infection with 48 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected tens of millions of 49 
people and led to over one million deaths(1). The proportion of patients with severe illness requiring 50 
admission to an intensive care unit (ICU) has been reported at between 4% and 32%(2), and 51 
concerns that ICU capacity may be overwhelmed have weighed heavily in policy considerations such 52 
as the implementation of lockdowns and social distancing(3).  53 
 54 
Cohorts of patients critically ill with COVID-19 have been described by authors from several 55 
countries, including China(4,5), Italy(6), Sweden(7) and the United States(8–10). From these studies 56 
we have learnt important lessons including the preponderance of males being affected, the 57 
association of increasing age with mortality, and the high prevalence of co-morbidities such as 58 
hypertension, diabetes and obesity. Patients most severely affected by COVID-19 are likely to be 59 
admitted to an ICU; understanding the demographic pattern of these patients and factors related to 60 
important clinical outcomes is essential. To date, peer-reviewed analysis of such patients in the 61 
United Kingdom (UK) has been limited to large scale epidemiological studies or focussed studies in 62 
small samples. We therefore conducted a prospective observational cohort study to better 63 
understand the clinical characteristics and outcomes of patients admitted to an ICU in the UK with 64 
severe COVID-19. Detailed analysis of this cohort is vital to gain insight into the factors associated 65 
with outcomes, guide planning for future waves of infection, and to inform clinical decision making 66 
and research. 67 
  68 
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Methods 69 
Study design and participants 70 
We performed a prospective observational cohort study at the Royal Free Hospital(11), a 520 bed 71 
teaching hospital in London, UK. The Royal Free Hospital is one of four designated centres for 72 
managing patients with airborne high consequence infectious diseases in the UK(12) and was the 73 
second hospital in the country to admit a patient with confirmed COVID-19. We enrolled all patients 74 
with laboratory confirmed SARS-CoV-2 infection admitted to the ICU from the first case until the cut-75 
off date for this study, 6 May 2020. This date was chosen because there were no further ICU 76 
admissions in the subsequent two weeks. Patients were identified by daily review of the ICU 77 
admission database. Follow-up was right-censored on 10 June 2020, giving at least 28 days’ follow-78 
up in every patient. The initial capacity of the ICU was 34 patients; this was scaled up to 70 patients 79 
at the height of the pandemic.  80 
 81 
A standard operating procedure for identification of patients requiring admission to the ICU was 82 
devised in line with the WHO guidance on the management of patients with COVID-19(13). Patients 83 
with critical COVID-19 infection, defined as the presence of ARDS, sepsis or septic shock, were 84 
admitted to the ICU unless this was contraindicated. Patients with severe COVID-19 infection, 85 
defined as respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 < 90% on room air, 86 
were kept under close observation. In line with guidance issued by the UK National Institute for 87 
Health and Care Excellence(14), the Clinical Frailty Score was calculated for every patient admitted 88 
to hospital. This, together with a holistic assessment of each patient’s condition, including their 89 
comorbidities, physiological reserve and their wishes and those of their families, were used to 90 
determine when admission to the ICU was likely to be futile. There were no exclusion criteria for the 91 
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study and there was no sample size calculation; the size of the cohort was determined by the 92 
number of patients admitted during the study period. 93 
 94 
Diagnosis of SARS-CoV-2 infection was made using RT-PCR of nasopharyngeal secretions, sputum or 95 
endotracheal aspirate. At the beginning of the pandemic all samples were sent to a regional 96 
reference laboratory operated by Public Health England; subsequently an in-house assay was 97 
developed and this was later supplemented by commercial assays. 98 
 99 
The study was classified as a non-interventional service evaluation using routinely collected patient 100 
data and was registered with the institutional audit department. The UK Policy Framework for 101 
Health and Social Care does not require ethical approval or explicit patient consent for such studies. 102 
 103 
Procedures 104 
We captured routinely collected patient data from paper-based and electronic health records using 105 
a standardised template derived from the International Severe Acute Respiratory and emerging 106 
Infection Consortium (ISARIC) case report form(15) together with additional variables hypothesised 107 
to be relevant, based on the published literature at the start of the study period. The dataset 108 
consisted of demographic characteristics (age, sex, self-reported ethnicity and body mass index 109 
[BMI]), comorbidities (hypertension, hyperlipidaemia, diabetes, ischaemic heart disease, chronic 110 
respiratory disease, smoking status, chronic kidney disease, end-stage renal failure [ESRF] requiring 111 
renal replacement therapy), details of the presenting illness including the nature of symptoms and 112 
their duration, the initial hospital course prior to ICU admission, physiological variables on hospital 113 
and ICU admission and on days 1, 3 and 7 of the ICU admission, details of treatments received on 114 
ICU and pathology and radiology reports. We classified cardiovascular and respiratory support 115 
according to the definitions used by the UK Intensive Care National Audit and Research Centre(16). 116 
 7 
 117 
Statistical Analysis 118 
We analysed the data using R version 4.0.0 with RStudio version 1.3.959. All of the authors had 119 
unrestricted access to the raw data. Missing data were not imputed. Continuous variables were 120 
summarised using medians and interquartile ranges with comparisons between groups using the 121 
Wilcoxon rank-sum test. Categorical variables were presented as numbers and percentages with 122 
comparisons between groups using the chi-square or Fisher exact tests. p-values have not been 123 
adjusted to take account of multiple comparisons. 124 
 125 
We used logistic regression to assess the factors associated with ICU survival. Only patients with 126 
completed ICU episodes (i.e. those who died on or were discharged alive from ICU, excluding those 127 
who were transferred out to other hospitals) were included in these analyses. We created two sets 128 
of models, the first employing patient characteristics and physiology on admission to ICU, and the 129 
second using physiology, treatments and complications during the ICU admission. We captured each 130 
patient’s most extreme physiological variables on days 1, 3 and 7 of the ICU admission. For each 131 
model set we performed univariable regressions using variables thought to be associated with 132 
survival based on the published literature and clinical experience. From these univariable models we 133 
selected those variables found to have a statistically significant association with outcome at the p < 134 
0.1 level and included them in a multivariable model. For each variable we presented the (adjusted) 135 
odds ratio for death together with the associated 95% confidence interval and p value. 136 
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Results 137 
Baseline characteristics 138 
Between 2 March and 6 May 2020, 156 patients were admitted to our ICU with COVID-19. 112 (72%) 139 
were male, the median (IQR) age was 62 (54 to 70) years and 89 (57%) patients were aged over 60 140 
years. The majority of the patients (89 [57%]) were overweight or obese (BMI ≥ 25 kg/m2). With 141 
regards to ethnicity, 36 (23%) were Asian and 32 (21%) were Black. 26 patients (17%) had no 142 
reported past medical history. The most common comorbidities were hypertension (81 [52%]), 143 
dyslipidaemia (56 [36%]) and diabetes mellitus (52 [33%]). Baseline demographic characteristics of 144 
the cohort are shown in Table 1 and comorbidities are shown in Figure 1. The number of admissions, 145 
discharges, transfers and deaths over time are show in Figure 2. By way of context, 738 patients with 146 
a laboratory-confirmed diagnosis of COVID-19 were admitted to the Royal Free Hospital over the 147 
same time period. Of the 582 who were not admitted to ICU, the median (IQR) age was 74 (59 to 85) 148 
years and 421 (72%) were aged over 60 years. The data for the hospital were derived from an 149 
administrative database that did not record clinical characteristics. 150 
 151 
Figure 1: Comorbidities at hospital admission 152 
Figure 2: Admissions, discharges, transfers and death over time 153 
  154 
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Table 1: Baseline characteristics of the population 155 
 156 
Characteristic N = 1561 
Gender  
Female 44 (28%) 
Male 112 (72%) 
Age 62 (54, 70) 
Age Group  
Under 20 0 (0%) 
20 to 40 8 (5.1%) 
40 to 60 59 (38%) 
60 to 80 86 (55%) 
80+ 3 (1.9%) 
Ethnicity  
White 73 (47%) 
Black 32 (21%) 
Asian 36 (23%) 
Other 15 (9.6%) 
BMI Group  
Under 18.5 0 (0%) 
18.5 to 25 67 (43%) 
25 to 30 58 (37%) 
30 to 40 20 (13%) 
40+ 11 (7.1%) 
1Statistics presented: n (%); median (IQR) 
 157 
Patients reported, on average, a one week history of symptoms at the time of hospital admission 158 
(median 7 days, IQR 5 to 10 days). The most common symptoms at the time of admission were 159 
breathlessness (127 [81%]), cough (125 [81%]) and fever (122 [78%]). The range of symptoms on 160 
admission is presented in Figure 3. 109 (70%) patients were initially admitted to a ward. For these 161 
patients, the median (IQR) length of stay prior to ICU admission was 55 (29 to 87) hours. 162 
 163 
Figure 3: Symptoms at hospital admission 164 
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Physiology 165 
Patients were profoundly hypoxaemic on admission to ICU, with a median ratio of arterial partial 166 
pressure of oxygen (PaO2) to inspired fraction of oxygen (FIO2) (P/F ratio) of 17.1 (IQR 13.2 to 21.3) 167 
kPa (approximately 125 mmHg). Compared to those patients who survived to ICU discharge, those 168 
who died had persistently lower P/F ratios (15.8 versus 17.9, p=0.017 on day 1), lower arterial pH 169 
(7.3 versus 7.4, p=0.031 on day 1) and higher arterial partial pressure of carbon dioxide (PaCO2) (6.0 170 
versus 5.5 kPa, p=0.040 on day 1) on days 1, 3 and 7 of admission. Furthermore, those patients who 171 
died had higher peak inspiratory pressure (PIP) on days 3 and 7; this was predominantly driven by a 172 
reduction of PIP in the group who survived and a rise of PIP in the group who died, reflecting 173 
changes in lung compliance over time. Patients who survived had lower peak noradrenaline doses 174 
on day 3 (0.10 versus 0.15 mcg/kg/min, p=0.030) and day 7 (0.07 versus 0.15 mcg/kg/min, p=0.003). 175 
Patients who died had higher positive cumulative fluid balance on the third (1,962 versus 1,350 ml, 176 
p=0.045) and seventh (4,645 versus 1,332 ml, p<0.001) days of admission compared to those who 177 
survived. There were no differences between those who died and those who survived in the lowest 178 
recorded mean arterial blood pressure or highest temperature. Physiological measures for patients 179 
with completed ICU episodes are presented in Table 2. 180 
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Table 2: Physiological measurements over time, stratified by ICU survival 181 
 182 
Characteristic Overall, N = 156 Died, N = 381 Surviving, N = 1181 p-value2 
Lowest P/F Ratio 
Day 1 17.1 (13.2 to 21.3) 15.8 (12.1 to 18.3) 17.9 (13.6 to 22.3) 0.017 
Day 3 17.7 (13.9 to 23.6) 16.1 (12.7 to 18.7) 18.2 (14.4 to 24.6) 0.006 
Day 7 17.6 (13.6 to 23.2) 12.9 (10.1 to 16.3) 19.2 (15.8 to 24.2) <0.001 
pH at the time of lowest P/F Ratio 
Day 1 7.4 (7.3 to 7.4) 7.3 (7.3 to 7.4) 7.4 (7.3 to 7.4) 0.031 
Day 3 7.4 (7.3 to 7.4) 7.3 (7.3 to 7.4) 7.4 (7.4 to 7.4) <0.001 
Day 7 7.4 (7.3 to 7.4) 7.4 (7.3 to 7.4) 7.4 (7.4 to 7.5) <0.001 
PaCO2 at the time of the lowest P/F Ratio (kPa) 
Day 1 5.7 (5.1 to 6.5) 6.0 (5.3 to 6.5) 5.5 (5.0 to 6.4) 0.040 
Day 3 6.1 (5.4 to 6.9) 6.8 (6.1 to 7.8) 5.8 (5.2 to 6.6) <0.001 
Day 7 5.9 (5.2 to 6.8) 6.3 (5.4 to 7.2) 5.8 (5.0 to 6.6) 0.029 
PEEP at the time of the lowest P/F ratio (cmH2O) 
Day 1 10.0 (10.0 to 12.0) 10.0 (10.0 to 12.5) 10.0 (10.0 to 12.0) 0.5 
Day 3 10.0 (9.0 to 12.0) 12.0 (10.0 to 12.5) 10.0 (8.0 to 12.0) 0.056 
Day 7 10.0 (8.0 to 12.0) 10.0 (8.2 to 12.4) 10.0 (8.0 to 12.0) 0.055 
PIP at the time of the lowest P/F Ratio (cmH2O) 
Day 1 27.0 (23.0 to 29.0) 27.0 (24.0 to 29.0) 26.0 (23.0 to 29.0) 0.4 
Day 3 26.0 (21.8 to 29.0) 27.0 (24.2 to 30.0) 26.0 (21.0 to 28.0) 0.034 
Day 7 25.0 (20.0 to 30.0) 30.0 (25.0 to 33.0) 24.0 (18.8 to 28.0) <0.001 
Cumulative fluid balance in 24 hours (ml) 
Day 1 648 (99 to 1334) 850 (450 to 1386) 600 (4 to 1220) 0.062 
Day 3 1700 (318 to 3022) 1962 (1250 to 3620) 1350 (-22 to 2590) 0.045 
Day 7 1888 (56 to 4726) 4645 (2963 to 6485) 1332 (-309 to 3493) <0.001 
Mean arterial blood pressure (mmHg) 
Day 1 68 (63 to 75) 68 (63 to 75) 68 (63 to 75) 0.9 
Day 3 68 (65 to 75) 65 (65 to 75) 68 (65 to 75) 0.7 
Day 7 71 (65 to 80) 70 (60 to 75) 74 (65 to 80) 0.2 
Maximum noradrenaline dose in 24 hours (mcg/kg/min) 
Day 1 0.11 (0.07 to 0.17) 0.13 (0.08 to 0.24) 0.11 (0.07 to 0.16) 0.2 
Day 3 0.11 (0.07 to 0.18) 0.15 (0.09 to 0.26) 0.10 (0.06 to 0.15) 0.030 
Day 7 0.10 (0.05 to 0.16) 0.15 (0.10 to 0.27) 0.07 (0.04 to 0.13) 0.003 
Maximum temperature in 24 hours (oC) 
Day 1 38.0 (37.2 to 38.8) 38.2 (37.4 to 38.8) 37.9 (37.2 to 38.8) 0.4 
Day 3 37.7 (37.1 to 38.5) 37.8 (37.1 to 38.2) 37.7 (37.2 to 38.5) 0.3 
Day 7 37.5 (37.2 to 37.9) 37.4 (37.1 to 37.9) 37.5 (37.2 to 37.9) 0.6 
1Statistics presented: median (IQR) 
2Statistical tests performed: Wilcoxon rank-sum test 
Patients who were transferred out or who were still on ICU at the time of analysis were classed as Surviving 
183 
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Treatments received on ICU 184 
136 (87%) patients were intubated for mechanical ventilation during their ICU admission, with this 185 
occurring less than one hour after ICU admission in 104 (67%) patients. 77 (57% of those intubated) 186 
patients were placed in the prone position for mechanical ventilation at some point during their ICU 187 
stay, while 95 (70% of those intubated) received neuromuscular blockade (over and above that given 188 
at the time of intubation). The median (IQR) time to administration of neuromuscular blockade was 189 
24 hours (0 to 48) and the median (IQR) time to prone positioning was 48 hours (0 to 96). 52 (38% of 190 
those intubated) patients ultimately underwent tracheostomy insertion to facilitate weaning from 191 
the ventilator; this occurred a median (IQR) of 15.8 days (12.6 to 21) after ICU admission. 192 
 193 
The majority of patients admitted to ICU required organ support in addition to mechanical 194 
ventilation. 119 (76%) patients required a single vasopressor drug while 35 (23%) patients required 195 
multiple vasopressor or inotropic medications. 44 (28%) patients required renal replacement 196 
therapy (continuous venovenous haemofiltration or haemodialysis), for a median (IQR) duration of 8 197 
(4 to 22) days. All patients received broad-spectrum antibiotics for the empirical treatment of super-198 
added bacterial pneumonia. Details of organ support are presented in Table 3. 199 
 200 
8 (5.1%) patients were enrolled in a randomised control trial of remdesivir versus placebo 201 
(clinicaltrials.gov registration number NCT04292899) and 15 (9.6%) patients were enrolled in the 202 
COVACTA trial of tocilizumab versus placebo (clinicaltrials.gov registration number NCT04320615). 203 
  204 
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Table 3: Organ support received on ICU 205 
 206 
Characteristic N = 1561 
Cardiovascular support (ICNARC definition)  
Advanced 35 (22%) 
Basic 119 (76%) 
None 2 (1.3%) 
Missing 0 (0%) 
Respiratory support (ICNARC definition)  
Advanced 141 (90%) 
Basic 15 (9.6%) 
None 0 (0%) 
Missing 0 (0%) 
Renal replacement therapy 44 (28%) 
Number of days of renal replacement therapy 8 (4 to 22) 
1Statistics presented: n (%); median (25% to 75%) 
 207 
Thromboembolic complications 208 
82 (53%) patients underwent clinically indicated computed tomography pulmonary angiography 209 
(CTPA) to diagnose or exclude pulmonary thromboembolism (PE). Criteria for CTPA included 210 
hypoxaemia out of keeping with the appearance of the lung fields on chest radiography, extremely 211 
high D-dimer or a D-dimer that rose or remained static despite improvement of other inflammatory 212 
markers, failure to improve despite 48 hours’ prone position ventilation, new onset dysrhythmia, or 213 
evidence of right heart strain on ECG or echocardiography. 44 patients (54% of those who 214 
underwent CTPA) were diagnosed with PE; the majority of these were lobar or segmental. Right 215 
heart strain was present in 15 patients (33% of those who underwent CTPA). Thromboembolic 216 
complications are presented in Table 4. 217 
  218 
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Table 4: Thromboembolic complications 219 
 220 
 221 
Characteristic N = 1561 
CTPA performed 82 (53%) 
PE diagnosed on CTPA 44 (54%) 
Level of PE  
Pulmonary trunk 6 (14%) 
Lobar 10 (23%) 
Segmental 22 (50%) 
Subsegmental 6 (14%) 
RV strain on CTPA 15 (33%) 
RV = Right ventricular 
Percentages are of the parent group 
1Statistics presented: n (%) 
 222 
Outcomes 223 
Of the 156 total admissions to ICU with COVID-19, 38 (24%) patients died on ICU, 23 (15%) patients 224 
were transferred out to other hospitals, 92 (59%) patients were discharged alive from ICU and the 225 
remaining 3 (2%) patients were still on ICU at the time of follow-up. Of the 23 patients transferred 226 
out, one patient was transferred to the regional referral centre for extracorporeal membrane 227 
oxygenation and 22 patients were sent to other hospitals to balance patient capacity in London. Of 228 
the 92 patients discharged from ICU 82 (89%) were subsequently discharged from hospital and one 229 
died on the ward. Considering all patients, including those transferred out, 116 (74%) patients 230 
survived to 30 days following ICU admission. Survival, stratified by age group and sex, is shown in 231 
Figure 4. The 23 patients transferred out to other hospitals and 3 patients still on ICU have been 232 
excluded from the analysis of outcomes. Of the 130 patients with completed ICU episodes, who 233 
were included in the logistic regression models, 92 (71%) patients survived and the median length of 234 
stay was 11.8 (6.6 to 28.7) days. 235 
 236 
Figure 4: Survival stratified by age and sex 237 
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In the first set of logistic regression models (Table 5), that employed patient characteristics on 238 
admission to ICU, age (OR 1.12 [95% CI 1.07-1.18]), Asian ethnicity (OR 2.57 [95% CI 1.02-6.57]), 239 
overweight or obese BMI (OR 1.90 [95% CI 0.87-4.33]), lowest P/F ratio on the first day of admission 240 
(OR 0.91 [95% CI 0.84-0.97]) and PaCO2 at the time of the lowest P/F ratio on the first day of 241 
admission (OR 1.40 [95% CI 1.02-1.95]) were associated with increased odds of death in univariable 242 
regression models, at a significance level of p < 0.1. Arterial pH at the time of the lowest P/F ratio on 243 
the first day of admission was significantly associated with death in the statistical sense although the 244 
effect size was negligible. In a multivariable model age (OR 1.13 [95% CI 1.07-1.21]), obesity (OR 3.06 245 
[95% CI 1.16-8.74]), lowest P/F ratio on the first day of admission (OR 0.90 [95% CI 0.81-0.98]) and 246 
PaCO2 (OR 1.52 [95% CI 1.01-2.39]) remained significant at the p < 0.05 level. 247 
 248 
Table 5: Relationships between factors on admission to ICU and outcome 249 
 250 
 Univariable Multivariable 
Characteristic N OR1 95% CI1 p-value OR1 95% CI1 p-value 
Age on admission 130 1.12 1.07, 1.18 <0.001 1.13 1.07, 1.21 <0.001 
Gender 130       
Female        
Male  1.27 0.54, 3.17 0.6    
Ethnicity 130       
White        
Black  0.87 0.30, 2.38 0.8 2.11 0.59, 7.60 0.2 
Asian  2.57 1.02, 6.57 0.046 2.94 0.94, 9.78 0.068 
Other  0.25 0.01, 1.45 0.2 0.41 0.02, 3.18 0.5 
BMI 130       
Normal Weight        
Overweight or Obese  1.90 0.87, 4.33 0.10 3.06 1.16, 8.74 0.029 
Smoking status 117 0.67 0.40, 1.08 0.12    
Any comorbidity 130 1.29 0.46, 4.21 0.7    
Lowest P/F ratio on first ICU day 126 0.91 0.84, 0.97 0.006 0.90 0.81, 0.98 0.016 
pH at time of lowest P/F ratio 126 0.01 0.00, 1.09 0.058    
PaCO2 at time of lowest P/F ratio 126 1.40 1.02, 1.95 0.041 1.52 1.01, 2.39 0.050 
1OR = Odds Ratio, CI = Confidence Interval 
 251 
 16 
In the second set of logistic regression models (Table 6), that evaluated events during ICU admission, 252 
age (OR 1.12 [95% CI 1.07-1.18]), lowest P/F ratio across days 1, 3 and of ICU admission (OR 0.80 253 
[95% CI 0.71-0.88]), highest PaCO2 across days 1, 3 and of ICU admission (OR 2.00 [95% CI 1.43-254 
2.89]), highest positive end-expiratory pressure (PEEP) across days 1, 3 and of ICU admission (OR 255 
1.15 [95% CI 0.99-1.35]), highest peak inspiratory pressure (PIP) across days 1, 3 and of ICU 256 
admission (OR 1.15 [95% CI 1.04-1.29]), peak noradrenaline dose across days 1, 3 and of ICU 257 
admission (OR 32.2 [95% CI 3.97-341]) and receiving neuromuscular blockade (OR 5.82 [95% CI 2.36-258 
16.6]) or receiving prone position ventilation (OR 3.37 [95% CI 1.54-7.73]) were associated with 259 
increased odds of death in univariable models, at a significance level of p < 0.1. In a multivariable 260 
model age (OR 1.17 [95% CI 1.09-1.27]), lowest P/F ratio (OR 0.82 [95% CI 0.67-0.98]) and peak 261 
noradrenaline dose (OR 33.0 [95% CI 1.61-860]) remained significantly associated with death at the 262 
p < 0.05 level. 263 
 264 
Table 6: Relationships between factors during ICU admission and outcome 265 
 266 
 Univariable Multivariable 
Characteristic N OR1 95% CI1 p-value OR1 95% CI1 p-value 
Age on admission 130 1.12 1.07, 1.18 <0.001 1.17 1.09, 1.27 <0.001 
Lowest P/F ratio during ICU admission 127 0.80 0.71, 0.88 <0.001 0.82 0.67, 0.98 0.036 
Lowest pH ratio during ICU admission 127 0.00 0.00, 0.01 <0.001    
Highest PaCO2 during ICU admission 127 2.00 1.43, 2.89 <0.001 1.30 0.74, 2.34 0.4 
Lowest PaO2 during ICU admission 127 0.70 0.45, 1.06 0.11    
Highest PEEP during ICU admission 117 1.15 0.99, 1.35 0.072 0.94 0.73, 1.20 0.6 
Highest PIP during ICU admission 112 1.15 1.04, 1.29 0.010 1.05 0.87, 1.27 0.6 
Highest noradrenaline dose during ICU 
admission 128 32.2 3.97, 341 0.002 33.0 1.61, 860 0.027 
Highest temperature during ICU admission 128 1.12 0.97, 1.70 0.3    
Intubated 130 2.46 0.76, 11.0 0.2    
Neuromuscular blockade 130 5.82 2.36, 16.6 <0.001 6.48 0.96, 53.4 0.064 
Prone position ventilation 130 3.37 1.54, 7.73 0.003 0.76 0.16, 3.56 0.7 
PE diagnosed during admission 73 1.28 0.48, 3.49 0.6    
Renal replacement therapy 130 1.66 0.74, 3.65 0.2    
1OR = Odds Ratio, CI = Confidence Interval 
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Discussion 267 
In this prospective observational cohort study, we found that patients admitted to the ICU of a 268 
London teaching hospital were mostly male, aged over 60 years and with a high prevalence of 269 
comorbidities. A substantial proportion were from ethnic minorities. Patients were critically ill with 270 
severe hypoxaemia, almost all received mechanical ventilation, the vast majority required 271 
cardiovascular support and there were high rates of renal failure and thromboembolic 272 
complications. 273 
 274 
Our study is one of the two largest single centre analyses, published to date, describing cohorts of 275 
critically ill patients with COVID-19 in Europe(7,17). Larsson and colleagues(7) reported on the 276 
characteristics and outcomes of 260 patients admitted to ICU at the Karolinska Institute in 277 
Stockholm, although almost one quarter of patients did not have a completed ICU episode at the 278 
time of analysis and their study lacked detailed information on physiological variables and 279 
treatments received on ICU. The UK Intensive Care National Audit and Research Centre (ICNARC) has 280 
published regular reports throughout the pandemic(16), summarised in a recent peer-reviewed 281 
publication(18). These analyses have been limited to physiological data from the first 24 hours of 282 
admission and have lacked detailed information on symptoms and disease-specific therapies 283 
received on ICU, such as prone position ventilation. Other reports from the UK include a study using 284 
administrative data to evaluate differences in mortality between hospitals(19), a study focussing on 285 
the use of risk scores to predict outcome in patients admitted to ICU with COVID-19(20), an analysis 286 
of the demographic characteristics of a small cohort of patients admitted to ICU(21), and a highly 287 
selected case-control series(22) published on the preprint server medRxiv.org. A large retrospective, 288 
telephone-based cohort study from Lombardy, Italy(6) conducted a comprehensive analysis of 289 
comorbidities, respiratory physiology and the use of prone position ventilation although their study 290 
was again limited to data from the first 24 hours of admission and only 42% of patients had a 291 
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completed ICU episode at the time of publication. Two recent systematic reviews(17,23) have 292 
summarised the available data from cohort studies around the world. 293 
 294 
The demographic characteristics of our patient cohort – almost three quarters male, more than half 295 
overweight or obese, more than 40% from ethnic minorities, more than half aged over 60 years – 296 
closely mirror those seen in other studies(6–8,10,18). The prevalence of comorbidities was high, 297 
with only 16% reporting no past medical history. Data from all ICUs in England, Wales, and Northern 298 
Ireland, as reported by ICNARC(18), found that 70% of patients were male, 74% were overweight or 299 
obese, and 36% were from ethnic minorities, with a median age of 60. These findings closely mirror 300 
those seen at our institution. Large cohort studies from New York City(8), Atlanta(10), Lombardy(6) 301 
and Stockholm(7) reached similar conclusions. It is noteworthy that raised BMI was associated with 302 
increased mortality in this current study, even after adjustment for possible confounding factors in a 303 
multivariable logistic regression model, with Asian ethnicity almost reaching the threshold for 304 
statistical significance. The proportion of patients of Asian or Black ethnicity admitted to our ICU 305 
with COVID-19 is much higher than would be expected given the makeup of the local population(24). 306 
Further research is urgently required to understand the mechanisms underpinning these 307 
observations, which have been consistently noted in a number of studies(18,21,25–27). 308 
 309 
The patients admitted to our ICU had severe hypoxaemic respiratory failure. Almost all patients 310 
required intubation and mechanical ventilation, in keeping with the New York(8), Atlanta(10), 311 
Lombardy(6) and Stockholm(7) cohorts, although the requirement for invasive ventilation was much 312 
higher than reported in Chinese studies(4,5,28–30). This may reflect differences in the use of non-313 
invasive ventilation between countries and the settings within the hospital where these therapies 314 
are provided, and highlights the importance of considering regional data when planning for potential 315 
future waves of the pandemic. 316 
 317 
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More than half of the intubated patients on our ICU required neuromuscular blockade and/or prone 318 
position ventilation; the use of these therapies was much higher than reported in early studies(6,8), 319 
although was similar to the findings of a more recent report from Norway(31). The association 320 
between neuromuscular blockade and prone position ventilation and death in univariable models is 321 
likely to reflect confounding by indication, whereby the most severely unwell patients, with 322 
refractory hypoxaemia, were more likely to be receive neuromuscular blockade and/or be placed in 323 
the prone position. Although there is high quality evidence of a mortality benefit from prone 324 
position ventilation in patients with ARDS(32), it is unclear whether this extends to patients with 325 
COVID-19. In the event of another wave of infection further studies are required to address this 326 
important question. Furthermore, the intense resource commitment required to safely ventilate 327 
large numbers of patients in the prone position should be borne in mind when planning for any 328 
future outbreaks of COVID-19 infection. 329 
 330 
The majority of patients admitted to our ICU had multiorgan failure, defined as the requirement for 331 
at least two of respiratory, cardiovascular or renal support, with almost three quarters requiring at 332 
least one vasoactive drug and more than one quarter requiring renal replacement therapy. The high 333 
prevalence of acute kidney injury in patients with COVID-19 has been widely reported (4,8,18,33)  334 
and requires urgent further investigation to understand the mechanisms involved. Similarly, high 335 
rates of renal replacement therapy have been reported in other UK ICUs(18) and in cohorts from 336 
New York(8), Dublin(34) and Stockholm(7) but not China(30,35). The requirement for multiorgan 337 
support must be borne in mind when it comes to planning for further waves of infection; it is clear 338 
that a focus on ICU ventilators, for example, will not be sufficient. Adequate plans to provide 339 
vasopressor and inotropic drugs by infusion, along with renal replacement therapy, must be made.  340 
 341 
A greater than expected number of patients in our cohort were diagnosed with a PE and more than 342 
one third of these had CT evidence of right ventricular dysfunction. Thromboembolic complications 343 
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have been widely reported in patients with COVID-19(36,37), including in patients admitted to 344 
ICU(38). Further work is required to understand the role of screening for PEs in patients admitted to 345 
ICU with COVID-19, and determine the most effective treatment strategy.  346 
 347 
Strengths of our study include its relatively large sample size, the complete ascertainment of all 348 
patients admitted to ICU with COVID-19 at our institution, the prospective design using a 349 
standardised, internationally recognised data collection tool, the granular and highly curated dataset 350 
collected on each patient through manual chart review, and follow-up for at least 28 days in every 351 
patient.  352 
 353 
Our study had a number of limitations. Like all observational designs it is subject to confounding and 354 
associations between exposures and outcomes should not be interpreted as causal relationships. 355 
The population admitted to ICU was a subset of those presenting to and admitted to hospital. 356 
Upstream triage of patients and the criteria used to identify those patients requiring (and suitable 357 
for) ICU admission will have affected the composition of our cohort and potentially the relationships 358 
between exposures and outcomes. The criteria used for ICU admission are likely to have varied 359 
between institutions and at different time points during the pandemic. As such, the findings in our 360 
cohort may differ from those in other studies, and they may not represent the entire population of 361 
patients severely ill with COVID-19. The lack of data concerning the population admitted to our 362 
hospital but not our ICU limits our ability to explore this inclusion bias is more detail, although it is 363 
reassuring to note the similarities between our findings and those of other cohorts. Physiological 364 
data were recorded on paper charts and as such only a small subset of observations could be 365 
digitised for analysis. A number of patients were transferred out of the hospital for logistical reasons 366 
and we were unable to gather information beyond their survival status once they left our ICU. This is 367 
likely to have biased in favour of increased mortality since the most stable patients were chosen for 368 
transfer. Although patients were transferred to our hospital from across London the local population 369 
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is not representative of London as a whole in terms of its ethnic and sociodemographic makeup. We 370 
have not controlled for multiple analyses and the possibility of type I error cannot be excluded. 371 
 372 
Conclusions 373 
In this large cohort of hypoxaemic critically ill patients admitted to an ICU in London with COVID-19, 374 
we demonstrated that age, obesity and degree of hypoxaemia were independently associated with 375 
increased odds of death. There was a strong signal towards an association between Asian ethnicity 376 
and death in univariable analyses. Multiple organ failure requiring support was common as was the 377 
diagnosis of PE. In the event of further waves of this pandemic in the UK, sufficient plans must be in 378 
place to cope with this expected pattern of disease and studies must be ready to explore the links 379 
between obesity, ethnicity and survival.   380 
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